Joseph Musaazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph Musaazi has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Barbara Castelnuovo
Affiliation Infectious Diseases Institute, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda
12 shared publicationsChristine Sekaggya-Wiltshire
Affiliations Infectious Diseases Institute, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda, School of Medicine, University of St Andrews, St Andrews, Scotland, United Kingdom
12 shared publications- Barbara Castelnuovo
Affiliation Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
11 shared publications Proscovia M. Namuwenge
Affiliation National Tuberculosis and Leprosy Program, Uganda Ministry of Health, Kampala, Uganda
11 shared publicationsM. Sanni Ali
Affiliations Department of Disease Control, LSHTM, London, United Kingdom, VIBRANIUM RESOURCES Foundation, Addis Ababa, Ethiopia
10 shared publicationsNele Brusselaers
Affiliations Global Health Institute, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
10 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0005829
Isoniazid monotherapy for tuberculosis prevention during pregnancy and adverse outcomes in women living with HIV in Uganda: A propensity score–weighted analysis of routine care data
Data on the safety of tuberculosis preventive treatment (TPT) during pregnancy particularly from routine care settings in high tuberculosis (TB) burden countries remain limited. We evaluated the association between TPT exposure during pregnancy and adverse pregnancy outcomes among pregnant women living with HIV (WLHIV) in Uganda. We conducted a retrospective cohort study using routinely collected data from five public urban primary health facilities in Kampala, Uganda. We included pregnant women living with HIV on antiretroviral therapy (ART) between 2016 and 2022. The primary outcome was a composite of adverse pregnancy outcomes: miscarriage, stillbirth, low birth weight, neonatal complications, or maternal/neonatal death. A secondary composite outcome excluded neonatal and maternal death. There was no preterm delivery documented in this sample. The primary exposure was 6-month isoniazid preventive therapy (IPT) during pregnancy. We applied inverse probability of treatment weighting (IPTW) using propensity scores from logistic regression to adjust for confounding. Missing data on covariates and outcome were addressed using multiple imputation. Analysis was performed using R software v.4.3.3. We analyzed data from 521 pregnant WLHIV, the median age was 28 years (interquartile range 24–31), 44% of whom received IPT during pregnancy. Overall, 10.0% experienced an adverse pregnancy outcome. No significant differences were observed between IPT-exposed and unexposed groups for the primary (10.3% vs. 9.6%; p = 0.81) or secondary (10.3% vs. 8.5%; p = 0.50) composite outcomes. IPTW-adjusted analysis showed no significant association between IPT exposure and adverse pregnancy outcomes (weighted OR: 1.06; 95% CI: 0.68–1.63; p = 0.81). Sensitivity and subgroup analyses yielded consistent findings. Exposure to 6-month isoniazid TPT during pregnancy was not statistically associated with adverse pregnancy outcomes among women on ART in routine care settings. Strengthened pharmacovigilance and systematic clinical reporting are essential to ensure maternal and neonatal safety as TPT coverage expands in high TB/HIV burden settings.
- 25 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0005829
Open AccessIsoniazid monotherapy for tuberculosis prevention during pregnancy and adverse outcomes in women living with HIV in Uganda: A propensity score–weighted analysis of routine care data
Data on the safety of tuberculosis preventive treatment (TPT) during pregnancy particularly from routine care settings in high tuberculosis (TB) burden countries remain limited. We evaluated the association between TPT exposure during pregnancy and adverse pregnancy outcomes among pregnant women living with HIV (WLHIV) in Uganda. We conducted a retrospective cohort study using routinely collected data from five public urban primary health facilities in Kampala, Uganda. We included pregnant women living with HIV on antiretroviral therapy (ART) between 2016 and 2022. The primary outcome was a composite of adverse pregnancy outcomes: miscarriage, stillbirth, low birth weight, neonatal complications, or maternal/neonatal death. A secondary composite outcome excluded neonatal and maternal death. There was no preterm delivery documented in this sample. The primary exposure was 6-month isoniazid preventive therapy (IPT) during pregnancy. We applied inverse probability of treatment weighting (IPTW) using propensity scores from logistic regression to adjust for confounding. Missing data on covariates and outcome were addressed using multiple imputation. Analysis was performed using R software v.4.3.3. We analyzed data from 521 pregnant WLHIV, the median age was 28 years (interquartile range 24–31), 44% of whom received IPT during pregnancy. Overall, 10.0% experienced an adverse pregnancy outcome. No significant differences were observed between IPT-exposed and unexposed groups for the primary (10.3% vs. 9.6%; p = 0.81) or secondary (10.3% vs. 8.5%; p = 0.50) composite outcomes. IPTW-adjusted analysis showed no significant association between IPT exposure and adverse pregnancy outcomes (weighted OR: 1.06; 95% CI: 0.68–1.63; p = 0.81). Sensitivity and subgroup analyses yielded consistent findings. Exposure to 6-month isoniazid TPT during pregnancy was not statistically associated with adverse pregnancy outcomes among women on ART in routine care settings. Strengthened pharmacovigilance and systematic clinical reporting are essential to ensure maternal and neonatal safety as TPT coverage expands in high TB/HIV burden settings.
- Open Access
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
Frailty and Other Ageing Phenotypes Among Older People Living With HIV Across a High- and Low-Income Setting: A Comparison of the HASA and GEPPO Cohorts
Background: The population of older people living with HIV is increasing worldwide. Comparative data on frailty and other geriatric syndromes across high- and low-income settings are limited. We compared frailty and other geriatric syndromes in two cohorts in Uganda and Italy.Methods: We performed a cross-sectional analysis of 500 HASA and 520 GEPPO participants (213 vs. 300 in the 65–75 subgroup). Frailty was assessed using the Fried phenotype. Analyses included overall cohort, subgroup analysis among participants aged 65–75 years, and age-sex standardized estimates. Multivariable ordinal logistic regression assessed whether residence in Uganda versus Italy was independently associated with higher frailty after adjustment for demographic and clinical characteristics.Findings: GEPPO participants were older, mostly male and had a higher prevalence of multimorbidity and polypharmacy (all p<0.01). Frailty prevalence was higher in GEPPO (13.3% vs. 8.4%; p<0.001), but did not differ in the 65–75 subgroup (6.6% vs. 8.5%; p=0.66). Of the frailty domains, shrinking predominated in HASA, while exhaustion, low physical activity, weakness, and slow walking speed were more common in GEPPO. Residence in Uganda was associated with higher odds of frailty (AOR 1·57, 95% CI 1·06–2·32), although this association was not statistically significant in the 65-75 subgroup (AOR 1.37, 95% CI 0.86–2.18; p=0.18).Interpretation: Frailty patterns differed between cohorts. In Uganda, weight loss (shrinking) was more relevant, whereas in Italy reduced physical performance, multimorbidity, and polypharmacy predominated. Interventions aimed at older people with HIV should consider these contextual differences when planning strategies to support healthy aging.
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFrailty and Other Ageing Phenotypes Among Older People Living With HIV Across a High- and Low-Income Setting: A Comparison of the HASA and GEPPO Cohorts
Background: The population of older people living with HIV is increasing worldwide. Comparative data on frailty and other geriatric syndromes across high- and low-income settings are limited. We compared frailty and other geriatric syndromes in two cohorts in Uganda and Italy.Methods: We performed a cross-sectional analysis of 500 HASA and 520 GEPPO participants (213 vs. 300 in the 65–75 subgroup). Frailty was assessed using the Fried phenotype. Analyses included overall cohort, subgroup analysis among participants aged 65–75 years, and age-sex standardized estimates. Multivariable ordinal logistic regression assessed whether residence in Uganda versus Italy was independently associated with higher frailty after adjustment for demographic and clinical characteristics.Findings: GEPPO participants were older, mostly male and had a higher prevalence of multimorbidity and polypharmacy (all p<0.01). Frailty prevalence was higher in GEPPO (13.3% vs. 8.4%; p<0.001), but did not differ in the 65–75 subgroup (6.6% vs. 8.5%; p=0.66). Of the frailty domains, shrinking predominated in HASA, while exhaustion, low physical activity, weakness, and slow walking speed were more common in GEPPO. Residence in Uganda was associated with higher odds of frailty (AOR 1·57, 95% CI 1·06–2·32), although this association was not statistically significant in the 65-75 subgroup (AOR 1.37, 95% CI 0.86–2.18; p=0.18).Interpretation: Frailty patterns differed between cohorts. In Uganda, weight loss (shrinking) was more relevant, whereas in Italy reduced physical performance, multimorbidity, and polypharmacy predominated. Interventions aimed at older people with HIV should consider these contextual differences when planning strategies to support healthy aging.
- Open Access
- 6 November 2025
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 380 (1938) , 20240402
Valganciclovir for cytomegalovirus viraemia in advanced HIV disease: a phase 2b randomized placebo-controlled trial of valganciclovir for cytomegalovirus viraemia in adults and adolescents with advanced HIV disease
Mortality among adults hospitalized with advanced HIV disease (AHD; CD4 20%; there is an urgent need to evaluate strategies to reduce mortality within this extremely high-risk group. Approximately 50% of adults with CD4 counts −1 have detectable cytomegalovirus (CMV) viraemia, and high-level CMV viraemia is associated with greater than double the hazard of death in this population. Despite this, there are no current treatment guidelines to inform treatment of CMV viraemia without end-organ disease in the context of AHD. The NIRVANA study is a double-blinded, placebo-controlled, multi-centre phase 2b trial to evaluate efficacy and safety of valganciclovir for patients with AHD and CMV viraemia. We will enrol 150 hospitalized adults and adolescents (aged ≥15 years) with CD4 500 IU ml −1 from two hospitals in Uganda and South Africa. Participants will be randomized 1 : 1 to either valganciclovir 900 mg orally or matched placebo for 28 days. Safety monitoring and CMV viral load testing will occur weekly until week 4, and thereafter at week 8 and at study termination at week 12. The primary endpoint is a composite of adverse events of special interest, re-hospitalization or death within 8 weeks. Secondary endpoints include median reduction in CMV viral load at day 28 and week 12, proportion with CMV below the limit of detection at weeks 2, 4, 8 and 12, mortality, grade ≥3 adverse events and serious adverse events, duration of hospitalization, tolerability, HIV treatment response, proportion with ganciclovir resistance and valganciclovir pharmacokinetics. Data from the NIRVANA phase 2 trial including valganciclovir pharmacokinetic data will be used to inform design of a multi-site phase 3 randomized controlled trial powered for survival to investigate whether valganciclovir reduces mortality among hospitalized adults with AHD-associated CMV viraemia.This article is part of the discussion meeting issue ‘The indirect effects of cytomegalovirus infection: mechanisms and consequences’.
- 6 November 2025
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 380 (1938) , 20240402
Open AccessValganciclovir for cytomegalovirus viraemia in advanced HIV disease: a phase 2b randomized placebo-controlled trial of valganciclovir for cytomegalovirus viraemia in adults and adolescents with advanced HIV disease
Mortality among adults hospitalized with advanced HIV disease (AHD; CD4 20%; there is an urgent need to evaluate strategies to reduce mortality within this extremely high-risk group. Approximately 50% of adults with CD4 counts −1 have detectable cytomegalovirus (CMV) viraemia, and high-level CMV viraemia is associated with greater than double the hazard of death in this population. Despite this, there are no current treatment guidelines to inform treatment of CMV viraemia without end-organ disease in the context of AHD. The NIRVANA study is a double-blinded, placebo-controlled, multi-centre phase 2b trial to evaluate efficacy and safety of valganciclovir for patients with AHD and CMV viraemia. We will enrol 150 hospitalized adults and adolescents (aged ≥15 years) with CD4 500 IU ml −1 from two hospitals in Uganda and South Africa. Participants will be randomized 1 : 1 to either valganciclovir 900 mg orally or matched placebo for 28 days. Safety monitoring and CMV viral load testing will occur weekly until week 4, and thereafter at week 8 and at study termination at week 12. The primary endpoint is a composite of adverse events of special interest, re-hospitalization or death within 8 weeks. Secondary endpoints include median reduction in CMV viral load at day 28 and week 12, proportion with CMV below the limit of detection at weeks 2, 4, 8 and 12, mortality, grade ≥3 adverse events and serious adverse events, duration of hospitalization, tolerability, HIV treatment response, proportion with ganciclovir resistance and valganciclovir pharmacokinetics. Data from the NIRVANA phase 2 trial including valganciclovir pharmacokinetic data will be used to inform design of a multi-site phase 3 randomized controlled trial powered for survival to investigate whether valganciclovir reduces mortality among hospitalized adults with AHD-associated CMV viraemia.This article is part of the discussion meeting issue ‘The indirect effects of cytomegalovirus infection: mechanisms and consequences’.
- Open Access
Associations with Prevalent Sexually Transmitted Infection Prevalence among Young Women Domestic Workers in Central Uganda
Objective: Our study aimed to determine the prevalence and correlates of sexually transmitted infections (STIs) among adolescent girls and young women (AGYW) employed as household domestic workers in Kampala, Uganda. Methods: Ugandan AGYW aged 14-24 participated in a community-based cross-sectional study in the Kampala Metropolitan Area from November 2023 to March 2024. Self-collected vaginal swabs were tested for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) using GeneXpert™. Testing for HIV and syphilis was performed using the Bioline™ HIV/syphilis Duo test. Correlates of STI prevalence were determined using modified Poisson regression. Results: Of 262 AGYW enrolled, the median age was 20 years (IQR 18-23), and 87 (33%) had an STI: Chlamydia trachomatis (27.5%), syphilis (5.7%), HIV (4.6%), and Neisseria gonorrhoea (1.5%). Overall, 14.9% had >1 STI. Of 12 AGYW with HIV, three (25%) were newly diagnosed, and 6/9 had detectable viral loads (≥1000 copies/ml). In the prior 12 months, 126 (48%) had received syndromic STI treatment, but only 35 (28%) notified their partners. Additionally, 102 (39%) had used emergency contraception, with 54% believing it was protective against STIs, including HIV. Factors associated with STI prevalence included receipt of non-cash (instead of salary) remuneration for domestic work (adjusted prevalence ratio [aPR] 2.26; 95% CI:1.04-4.92; P=0.040), lower education attainment (aPR 1.73; 95% CI: 1.16-2.57; P=0.007), alcohol consumption in past six months (aPR 1.72; 95% CI: 1.12-2.64; P=0.013) and transactional sex during the past six months (aPR 1.43; 95% CI: 1.01-2.04; P=0.045). Conversely, self-reported sexual abuse was negatively associated with STIs (aPR 0.48; 95% CI: 0.28-0.83; P=0.008). Conclusion: The high prevalence of undiagnosed STIs and unsuppressed HIV among AGYW domestic workers in Kampala highlights the urgent need to increase HIV/STI prevention, testing and treatment coverage for these underserved and vulnerable young women. Targeted interventions are needed to mitigate STI/HIV acquisition in this population. What is already known on this topic - summarise the state of scientific knowledge on this subject before you did your study, and why this study needed to be done.: Adolescent girls and young women (AGYW) in Uganda who are out of school and employed in household domestic work are a highly vulnerable population, often migrating from rural communities to cities with consequent social isolation, and are subject to unequal power dynamics with employers. This puts them at risk of intergenerational and transactional sex. The prevalence of STIs and HIV, and the associated socio-behavioural factors, have been poorly studied in this demographic, limiting the development of interventions for this group. What this study adds - summarise what we now know as a result of this study that we did not know before.: This cross-sectional study, which estimated STI and HIV prevalence among young females employed in household domestic work, found that one-third of AGYW domestic workers were diagnosed with at least one STI. The findings reveal a high burden of STIs and HIV, with many experiencing co-infections. Contributing factors such as poor working conditions, limited educational attainment and prevalent sexual behaviours associated with STIs– including transactional sex, sexual abuse, alcohol use, and inconsistent condom use– exacerbate their vulnerability. How this study might affect research, practice, or policy - summarise the implications of this study.: This research provides insights into STI and HIV risks for vulnerable AGYW employed in domestic work. It highlights the need for tailored HIV and STI interventions that focus on increased awareness, economic and educational empowerment, improved working conditions, socio-behavioural changes, legal redress, as well as expanded access to STI/HIV testing and treatment services for this hard-to-reach population.
Open AccessAssociations with Prevalent Sexually Transmitted Infection Prevalence among Young Women Domestic Workers in Central Uganda
Objective: Our study aimed to determine the prevalence and correlates of sexually transmitted infections (STIs) among adolescent girls and young women (AGYW) employed as household domestic workers in Kampala, Uganda. Methods: Ugandan AGYW aged 14-24 participated in a community-based cross-sectional study in the Kampala Metropolitan Area from November 2023 to March 2024. Self-collected vaginal swabs were tested for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) using GeneXpert™. Testing for HIV and syphilis was performed using the Bioline™ HIV/syphilis Duo test. Correlates of STI prevalence were determined using modified Poisson regression. Results: Of 262 AGYW enrolled, the median age was 20 years (IQR 18-23), and 87 (33%) had an STI: Chlamydia trachomatis (27.5%), syphilis (5.7%), HIV (4.6%), and Neisseria gonorrhoea (1.5%). Overall, 14.9% had >1 STI. Of 12 AGYW with HIV, three (25%) were newly diagnosed, and 6/9 had detectable viral loads (≥1000 copies/ml). In the prior 12 months, 126 (48%) had received syndromic STI treatment, but only 35 (28%) notified their partners. Additionally, 102 (39%) had used emergency contraception, with 54% believing it was protective against STIs, including HIV. Factors associated with STI prevalence included receipt of non-cash (instead of salary) remuneration for domestic work (adjusted prevalence ratio [aPR] 2.26; 95% CI:1.04-4.92; P=0.040), lower education attainment (aPR 1.73; 95% CI: 1.16-2.57; P=0.007), alcohol consumption in past six months (aPR 1.72; 95% CI: 1.12-2.64; P=0.013) and transactional sex during the past six months (aPR 1.43; 95% CI: 1.01-2.04; P=0.045). Conversely, self-reported sexual abuse was negatively associated with STIs (aPR 0.48; 95% CI: 0.28-0.83; P=0.008). Conclusion: The high prevalence of undiagnosed STIs and unsuppressed HIV among AGYW domestic workers in Kampala highlights the urgent need to increase HIV/STI prevention, testing and treatment coverage for these underserved and vulnerable young women. Targeted interventions are needed to mitigate STI/HIV acquisition in this population. What is already known on this topic - summarise the state of scientific knowledge on this subject before you did your study, and why this study needed to be done.: Adolescent girls and young women (AGYW) in Uganda who are out of school and employed in household domestic work are a highly vulnerable population, often migrating from rural communities to cities with consequent social isolation, and are subject to unequal power dynamics with employers. This puts them at risk of intergenerational and transactional sex. The prevalence of STIs and HIV, and the associated socio-behavioural factors, have been poorly studied in this demographic, limiting the development of interventions for this group. What this study adds - summarise what we now know as a result of this study that we did not know before.: This cross-sectional study, which estimated STI and HIV prevalence among young females employed in household domestic work, found that one-third of AGYW domestic workers were diagnosed with at least one STI. The findings reveal a high burden of STIs and HIV, with many experiencing co-infections. Contributing factors such as poor working conditions, limited educational attainment and prevalent sexual behaviours associated with STIs– including transactional sex, sexual abuse, alcohol use, and inconsistent condom use– exacerbate their vulnerability. How this study might affect research, practice, or policy - summarise the implications of this study.: This research provides insights into STI and HIV risks for vulnerable AGYW employed in domestic work. It highlights the need for tailored HIV and STI interventions that focus on increased awareness, economic and educational empowerment, improved working conditions, socio-behavioural changes, legal redress, as well as expanded access to STI/HIV testing and treatment services for this hard-to-reach population.
- Open Access
- 23 February 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (2) , e0268935
Increased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: A retrospective review of routinely collected data at six urban public health facilities in Uganda
Tuberculosis preventive therapy (TPT) effectively decreases rates of developing active tuberculosis disease in people living with HIV (PLHIV) who are at increased risk. The Uganda Ministry of Health launched a 100-day campaign to scale-up TPT in PLHIV in July 2019. We sought to examine the effect of the campaign on trends of TPT uptake and characteristics associated with TPT uptake and completion among persons in HIV care. We retrospectively reviewed routinely collected data from 2016 to 2019 at six urban public health facilities in Uganda. HIV care database and paper-based TPT registers at six public health facilities in Kampala, Uganda were retrospectively reviewed. Estimated trends of TPT (given as Isoniazid monotherapy) uptake and completion across the 4 years, among PLHIV aged 15 years and above, and factors associated, were examined using Poisson regression model with robust standard errors using generalized estimating equation (GEE) models. On average, a total of 39,774 PLHIV aged 15 years and above were eligible for TPT each calendar year at the six health facilities. Across all 4 years, more than 70% were females (range: 73.5% -74.6%) and the median age ranged from 33 to 34 years. From 2016 quarter one to 2019 quarter two, TPT uptake was consistently below 25%, but, as expected, the uptake significantly increased by about 3-folds from 22.1% to 61.2%, in 2019 quarter two (i.e. before the roll-out of the 100-day accelerated TPT intervention) and quarter three (i.e. after the roll-out of the 100-day accelerated TPT intervention) respectively. This increase remained highly significant even after adjusting for patients’ baseline characteristics (adjusted prevalence ratio [aPR] = 2.58 [95%CI 2.45, 2.72], P-value<0.001). TPT completion was consistently high at above 70% at most of the time, but, it increased significantly among those initiated during 2018 quarter four and in the subsequent two quarters after the roll-out of the 100-day accelerated TPT intervention (i.e. TPT completion was: 83.2%, 95.3%, and 97.1% among individuals initiated during 2018 quarter4, and 2019 quarters 1 and 2, respectively). The increase in TPT completion during this period remained significant even after adjusting for patients’ baseline characteristics (aPR [95%CI] = 1.09 [1.04, 1.14], P value<0.001, and 1.10 [1.05,1.15], P value<0.001, for individuals initiated during 2019 quarter 1, and 2, respectively compared to those initiated during 2018 quarter 4). Not on ART or newly started on ART compared to ART experienced, and pregnant at TPT initiation compared to not pregnant were associated with poor TPT completion, whereas older age (≥25 years versus 15–24 years) was associated with higher TPT completion. The targeted 100-day campaign dramatically increased TPT uptake and completion among PLHIV suggesting a viable catch up strategy to meet WHO guidelines. Future analysis with additional years of data post 100-days TPT intervention is required to evaluate the sustainability of the observed gains.
- 23 February 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (2) , e0268935
Open AccessIncreased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: A retrospective review of routinely collected data at six urban public health facilities in Uganda
Tuberculosis preventive therapy (TPT) effectively decreases rates of developing active tuberculosis disease in people living with HIV (PLHIV) who are at increased risk. The Uganda Ministry of Health launched a 100-day campaign to scale-up TPT in PLHIV in July 2019. We sought to examine the effect of the campaign on trends of TPT uptake and characteristics associated with TPT uptake and completion among persons in HIV care. We retrospectively reviewed routinely collected data from 2016 to 2019 at six urban public health facilities in Uganda. HIV care database and paper-based TPT registers at six public health facilities in Kampala, Uganda were retrospectively reviewed. Estimated trends of TPT (given as Isoniazid monotherapy) uptake and completion across the 4 years, among PLHIV aged 15 years and above, and factors associated, were examined using Poisson regression model with robust standard errors using generalized estimating equation (GEE) models. On average, a total of 39,774 PLHIV aged 15 years and above were eligible for TPT each calendar year at the six health facilities. Across all 4 years, more than 70% were females (range: 73.5% -74.6%) and the median age ranged from 33 to 34 years. From 2016 quarter one to 2019 quarter two, TPT uptake was consistently below 25%, but, as expected, the uptake significantly increased by about 3-folds from 22.1% to 61.2%, in 2019 quarter two (i.e. before the roll-out of the 100-day accelerated TPT intervention) and quarter three (i.e. after the roll-out of the 100-day accelerated TPT intervention) respectively. This increase remained highly significant even after adjusting for patients’ baseline characteristics (adjusted prevalence ratio [aPR] = 2.58 [95%CI 2.45, 2.72], P-value<0.001). TPT completion was consistently high at above 70% at most of the time, but, it increased significantly among those initiated during 2018 quarter four and in the subsequent two quarters after the roll-out of the 100-day accelerated TPT intervention (i.e. TPT completion was: 83.2%, 95.3%, and 97.1% among individuals initiated during 2018 quarter4, and 2019 quarters 1 and 2, respectively). The increase in TPT completion during this period remained significant even after adjusting for patients’ baseline characteristics (aPR [95%CI] = 1.09 [1.04, 1.14], P value<0.001, and 1.10 [1.05,1.15], P value<0.001, for individuals initiated during 2019 quarter 1, and 2, respectively compared to those initiated during 2018 quarter 4). Not on ART or newly started on ART compared to ART experienced, and pregnant at TPT initiation compared to not pregnant were associated with poor TPT completion, whereas older age (≥25 years versus 15–24 years) was associated with higher TPT completion. The targeted 100-day campaign dramatically increased TPT uptake and completion among PLHIV suggesting a viable catch up strategy to meet WHO guidelines. Future analysis with additional years of data post 100-days TPT intervention is required to evaluate the sustainability of the observed gains.
- Open Access
- 7 February 2023
- Published by MDPI AG in European Burn Journal
- Vol. 4 (1) , 69-79
Microbiological Findings and Clinical Outcomes in Ugandan Patients with Infected Burn Wounds
Nosocomial wound infections are a dreaded complication in patients with burns. However, access to the necessary microbiological diagnostics is impaired in low-resource settings. This prospective observational cohort study aimed to describe the bacterial pathogens, resistance profiles and clinical outcomes of patients with wound infections admitted to the largest specialized unit for burns and plastic surgery in Uganda. Blood and wound swab cultures were taken for bacterial species identification and antibiotic susceptibility testing. A total of 140 patients (female: n = 62, 44.3%) with a median age of 26 (IQR 7–35) years were included between October 2020 and April 2022, of which the majority (n = 101, 72.2%) had burn wounds (72.3% Grade 2b, 14.9% Grade 3). Gram-negative Enterobacterales, Pseudomonas spp. and Acinetobacter spp. were most commonly isolated from wound swabs and nearly all isolates were multidrug resistant with very limited treatment options. While the clinical outcome was favorable in 21 (15%) study participants, the majority were left with disabilities (minor: n = 41, 29.3%, moderate: n = 52, 37%, major: n = 14 (10%)). Twelve (8.6%) study participants died, mostly of Gram-negative sepsis. Our findings highlight the urgent need for routine access to microbiological diagnostics to improve patient care and local surveillance efforts on antimicrobial resistance.
- 7 February 2023
- Published by MDPI AG in European Burn Journal
- Vol. 4 (1) , 69-79
Open AccessMicrobiological Findings and Clinical Outcomes in Ugandan Patients with Infected Burn Wounds
Nosocomial wound infections are a dreaded complication in patients with burns. However, access to the necessary microbiological diagnostics is impaired in low-resource settings. This prospective observational cohort study aimed to describe the bacterial pathogens, resistance profiles and clinical outcomes of patients with wound infections admitted to the largest specialized unit for burns and plastic surgery in Uganda. Blood and wound swab cultures were taken for bacterial species identification and antibiotic susceptibility testing. A total of 140 patients (female: n = 62, 44.3%) with a median age of 26 (IQR 7–35) years were included between October 2020 and April 2022, of which the majority (n = 101, 72.2%) had burn wounds (72.3% Grade 2b, 14.9% Grade 3). Gram-negative Enterobacterales, Pseudomonas spp. and Acinetobacter spp. were most commonly isolated from wound swabs and nearly all isolates were multidrug resistant with very limited treatment options. While the clinical outcome was favorable in 21 (15%) study participants, the majority were left with disabilities (minor: n = 41, 29.3%, moderate: n = 52, 37%, major: n = 14 (10%)). Twelve (8.6%) study participants died, mostly of Gram-negative sepsis. Our findings highlight the urgent need for routine access to microbiological diagnostics to improve patient care and local surveillance efforts on antimicrobial resistance.
- Open Access
- 30 December 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (12) , e0000569
Adherence monitoring methods to measure virological failure in people living with HIV on long-term antiretroviral therapy in Uganda
Appointment keeping and self-report within 7-day or and 30-days recall periods are non-objective measures of antiretroviral treatment (ART) adherence. We assessed incidence of virological failure (VF), predictive performance and associations of these adherence measures with VF among adults on long-term ART. Data for persons initiated on ART between April 2004 and April 2005, enrolled in a long-term ART cohort at 10-years on ART (baseline) and followed until December 2021 was analyzed. VF was defined as two consecutives viral loads ≥1000 copies/ml at least within 3-months after enhanced adherence counselling. We estimated VF incidence using Kaplan-Meier and Cox-proportional hazards regression for associations between each adherence measure (analyzed as time-dependent annual values) and VF. The predictive performance of appointment keeping and self-reporting for identifying VF was assessed using receiver operating characteristic curves and reported as area under the curve (AUC). We included 900 of 1,000 participants without VF at baseline: median age was 47 years (Interquartile range: 41–51), 60% were women and 88% were virally suppressed. ART adherence was ≥95% for all three adherence measures. Twenty-one VF cases were observed with an incidence rate of 4.37 per 1000 person-years and incidence risk of 2.4% (95% CI: 1.6%-3.7%) over the 5-years of follow-up. Only 30-day self-report measure was associated with lower risk of VF, adjusted hazard ratio (aHR) = 0.14, 95% CI:0.05–0.37). Baseline CD4 count ≥200cells/ml was associated with lower VF for all adherence measures. The 30-day self-report measure demonstrated the highest predictive performance for VF (AUC = 0.751) compared to appointment keeping (AUC = 0.674), and 7-day self-report (AUC = 0.687). The incidence of virological failure in this study cohort was low. Whilst 30- day self-report was predictive, appointment keeping and 7-day self-reported adherence measures had low predictive performance in identifying VF. Viral load monitoring remains the gold standard for adherence monitoring and confirming HIV treatment response.
- 30 December 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (12) , e0000569
Open AccessAdherence monitoring methods to measure virological failure in people living with HIV on long-term antiretroviral therapy in Uganda
Appointment keeping and self-report within 7-day or and 30-days recall periods are non-objective measures of antiretroviral treatment (ART) adherence. We assessed incidence of virological failure (VF), predictive performance and associations of these adherence measures with VF among adults on long-term ART. Data for persons initiated on ART between April 2004 and April 2005, enrolled in a long-term ART cohort at 10-years on ART (baseline) and followed until December 2021 was analyzed. VF was defined as two consecutives viral loads ≥1000 copies/ml at least within 3-months after enhanced adherence counselling. We estimated VF incidence using Kaplan-Meier and Cox-proportional hazards regression for associations between each adherence measure (analyzed as time-dependent annual values) and VF. The predictive performance of appointment keeping and self-reporting for identifying VF was assessed using receiver operating characteristic curves and reported as area under the curve (AUC). We included 900 of 1,000 participants without VF at baseline: median age was 47 years (Interquartile range: 41–51), 60% were women and 88% were virally suppressed. ART adherence was ≥95% for all three adherence measures. Twenty-one VF cases were observed with an incidence rate of 4.37 per 1000 person-years and incidence risk of 2.4% (95% CI: 1.6%-3.7%) over the 5-years of follow-up. Only 30-day self-report measure was associated with lower risk of VF, adjusted hazard ratio (aHR) = 0.14, 95% CI:0.05–0.37). Baseline CD4 count ≥200cells/ml was associated with lower VF for all adherence measures. The 30-day self-report measure demonstrated the highest predictive performance for VF (AUC = 0.751) compared to appointment keeping (AUC = 0.674), and 7-day self-report (AUC = 0.687). The incidence of virological failure in this study cohort was low. Whilst 30- day self-report was predictive, appointment keeping and 7-day self-reported adherence measures had low predictive performance in identifying VF. Viral load monitoring remains the gold standard for adherence monitoring and confirming HIV treatment response.
- Open Access
- 3 June 2022
- Published by Johns Hopkins School Bloomberg School of Public Health, Center for Communication Programs in Global Health: Science and Practice
- Vol. 10 (3) , e2100661
Evaluation of Community Perceptions and Prevention Practices Related to Ebola Virus as Part of Outbreak Preparedness in Uganda, 2020
Introduction: During the 2018–2020 Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo, risk communication and community engagement (RCCE) were prioritized in geographic areas in Uganda considered at high risk of introduction of EVD. To inform EVD preparedness in Uganda, we evaluated community perceptions and prevention practices related to EVD in 6 districts in Uganda. Methods: In March 2020, we conducted a population-based survey in 6 purposively selected districts in Uganda using multistage cluster sampling. We examined differences between districts classified as high- versus low risk for EVD in terms of their message exposure from RCCE; risk perception; and EVD knowledge, attitudes, and prevention practices. Results: A total of 3,485 respondents were interviewed (91% response rate). EVD message exposure was more common in the high- versus low-risk districts. EVD risk perceptions were low overall but greater in the high- versus low-risk districts. Comprehensive knowledge was significantly greater in the high- versus low-risk districts (adjusted prevalence ratio [aPR] 1.61, 95% confidence interval [CI]=1.35, 1.93). Respondents9 engagement in all 3 EVD prevention practices (frequent handwashing with soap, avoiding physical contact with suspected Ebola patients, and avoiding burials involving contact with a corpse) was very low (4%). However, respondents with comprehensive knowledge were more likely to engage in all 3 EVD prevention practices compared to respondents without comprehensive knowledge (aPR 1.87, 95% CI=1.08, 3.25). Conclusion: Our findings suggest that while RCCE efforts as part of EVD outbreak preparedness may have contributed to higher EVD knowledge in the targeted high-risk districts, uptake of prevention behaviors was similarly low across districts. In a non-outbreak setting, implementing targeted RCCE strategies may not be sufficient to motivate people to adopt protective behaviors in the absence of a high threshold of perceived threat such as in an active outbreak. Key Findings Individuals in Ebola virus disease (EVD) high-risk districts reported greater EVD message exposure and comprehensive knowledge compared to individuals in EVD low-risk districts. Individuals with comprehensive knowledge of EVD were more likely to self-report frequent handwashing with soap, avoiding physical contact with suspected Ebola patients, and avoiding funerals/burials that involve physical contact with a corpse. Rejection of EVD misconceptions was not significantly associated with self-reported EVD-related prevention practices. Key Implications Efforts to promote EVD comprehensive knowledge may facilitate the uptake of EVD prevention practices. Risk communication and community engagement efforts continue to be critical for EVD preparedness and response efforts, especially in high-risk geographic areas.
- 3 June 2022
- Published by Johns Hopkins School Bloomberg School of Public Health, Center for Communication Programs in Global Health: Science and Practice
- Vol. 10 (3) , e2100661
Open AccessEvaluation of Community Perceptions and Prevention Practices Related to Ebola Virus as Part of Outbreak Preparedness in Uganda, 2020
Introduction: During the 2018–2020 Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo, risk communication and community engagement (RCCE) were prioritized in geographic areas in Uganda considered at high risk of introduction of EVD. To inform EVD preparedness in Uganda, we evaluated community perceptions and prevention practices related to EVD in 6 districts in Uganda. Methods: In March 2020, we conducted a population-based survey in 6 purposively selected districts in Uganda using multistage cluster sampling. We examined differences between districts classified as high- versus low risk for EVD in terms of their message exposure from RCCE; risk perception; and EVD knowledge, attitudes, and prevention practices. Results: A total of 3,485 respondents were interviewed (91% response rate). EVD message exposure was more common in the high- versus low-risk districts. EVD risk perceptions were low overall but greater in the high- versus low-risk districts. Comprehensive knowledge was significantly greater in the high- versus low-risk districts (adjusted prevalence ratio [aPR] 1.61, 95% confidence interval [CI]=1.35, 1.93). Respondents9 engagement in all 3 EVD prevention practices (frequent handwashing with soap, avoiding physical contact with suspected Ebola patients, and avoiding burials involving contact with a corpse) was very low (4%). However, respondents with comprehensive knowledge were more likely to engage in all 3 EVD prevention practices compared to respondents without comprehensive knowledge (aPR 1.87, 95% CI=1.08, 3.25). Conclusion: Our findings suggest that while RCCE efforts as part of EVD outbreak preparedness may have contributed to higher EVD knowledge in the targeted high-risk districts, uptake of prevention behaviors was similarly low across districts. In a non-outbreak setting, implementing targeted RCCE strategies may not be sufficient to motivate people to adopt protective behaviors in the absence of a high threshold of perceived threat such as in an active outbreak. Key Findings Individuals in Ebola virus disease (EVD) high-risk districts reported greater EVD message exposure and comprehensive knowledge compared to individuals in EVD low-risk districts. Individuals with comprehensive knowledge of EVD were more likely to self-report frequent handwashing with soap, avoiding physical contact with suspected Ebola patients, and avoiding funerals/burials that involve physical contact with a corpse. Rejection of EVD misconceptions was not significantly associated with self-reported EVD-related prevention practices. Key Implications Efforts to promote EVD comprehensive knowledge may facilitate the uptake of EVD prevention practices. Risk communication and community engagement efforts continue to be critical for EVD preparedness and response efforts, especially in high-risk geographic areas.
- Open Access
Survival and predictors of mortality after completion of TB treatment among people living with HIV
Background: After completion of TB treatment patients may remain at-risk of complications and mortality. We determined the survival and predictors of all-cause mortality after completing TB treatment among ART experienced patients. Methods: This was a retrospective cohort analysis of all ART experienced patients who completed TB treatment at a specialist HIV clinic in Uganda, between 2009 and 2014. The patients were followed for five years after TB treatment. We determined mortality rate, probability of death, and predictors of all-cause mortality after TB treatment using Poisson methods, Kaplan-Meier methods, and Cox proportional hazard models, respectively. Results: A total 1,287 patients completed TB treatment between 2009 and 2014, of which 1,111 were included in the analysis. At TB treatment completion, the median age was 36 years (IQR: 31-42), 563 (50.7%) were males, and median CD4 count was 235 cells/mL (IQR: 139-366). The person time at risk was 4410.60 person-years. The all-cause mortality rate was 15.42 per 1000 person-years (95% CI: 12.14-19.59). The probability of death at five years was 6.9% (95%CI: 5.5%-8.8%). In the multivariable analysis, CD4 countp =0.03) alongside TB history (aHR=2.12, 95%CI: 1.16 - 3.85, p =0.01). Conclusion: Survival post TB treatment in ART experienced PLHIV is reasonably good and most deaths occur within two years of TB treatment completion. Patients with low CD4 and those with history of treatment have an increased risk of mortality which underscores the need for TB prophylaxis, detailed assessment, and close monitoring after TB treatment. What is already known on this topic: Tuberculosis is the leading cause of death in PLHIV and patients who complete treatment remain at risk of mortality. However, it is not clear what the mortality rate is, when it occurs, and what factors are associated with mortality in exclusively ART experienced patients. What this study adds: Most deaths occur within two years after treatment completion decreasing drastically by year five. Patients with low CD4 count after TB treatment have an 81% increased risk of death and those with a history of TB have a 200% increased risk of mortality. How this study might affect research, practice or policy: The study provides a detailed understanding of post-TB survival in ART experienced PLHIV and underscores the need for programs and clinics to re-define TB treatment success and consider the use of enhanced prophylaxis after TB treatment.
Open AccessSurvival and predictors of mortality after completion of TB treatment among people living with HIV
Background: After completion of TB treatment patients may remain at-risk of complications and mortality. We determined the survival and predictors of all-cause mortality after completing TB treatment among ART experienced patients. Methods: This was a retrospective cohort analysis of all ART experienced patients who completed TB treatment at a specialist HIV clinic in Uganda, between 2009 and 2014. The patients were followed for five years after TB treatment. We determined mortality rate, probability of death, and predictors of all-cause mortality after TB treatment using Poisson methods, Kaplan-Meier methods, and Cox proportional hazard models, respectively. Results: A total 1,287 patients completed TB treatment between 2009 and 2014, of which 1,111 were included in the analysis. At TB treatment completion, the median age was 36 years (IQR: 31-42), 563 (50.7%) were males, and median CD4 count was 235 cells/mL (IQR: 139-366). The person time at risk was 4410.60 person-years. The all-cause mortality rate was 15.42 per 1000 person-years (95% CI: 12.14-19.59). The probability of death at five years was 6.9% (95%CI: 5.5%-8.8%). In the multivariable analysis, CD4 countp =0.03) alongside TB history (aHR=2.12, 95%CI: 1.16 - 3.85, p =0.01). Conclusion: Survival post TB treatment in ART experienced PLHIV is reasonably good and most deaths occur within two years of TB treatment completion. Patients with low CD4 and those with history of treatment have an increased risk of mortality which underscores the need for TB prophylaxis, detailed assessment, and close monitoring after TB treatment. What is already known on this topic: Tuberculosis is the leading cause of death in PLHIV and patients who complete treatment remain at risk of mortality. However, it is not clear what the mortality rate is, when it occurs, and what factors are associated with mortality in exclusively ART experienced patients. What this study adds: Most deaths occur within two years after treatment completion decreasing drastically by year five. Patients with low CD4 count after TB treatment have an 81% increased risk of death and those with a history of TB have a 200% increased risk of mortality. How this study might affect research, practice or policy: The study provides a detailed understanding of post-TB survival in ART experienced PLHIV and underscores the need for programs and clinics to re-define TB treatment success and consider the use of enhanced prophylaxis after TB treatment.
- Open Access
Increased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: A retrospective review of routinely collected data at six urban public health facilities in Uganda
Introduction Tuberculosis preventive therapy (TPT) effectively decreases rates of tuberculosis reactivation in people living with HIV (PLHIV) who are at increased risk. The Uganda Ministry of Health launched a 100-day campaign to scale-up TPT in PLHIV in July 2019. We sought to examine the effect of the campaign on trends of TPT uptake and characteristics associated with TPT uptake and TPT completion among persons in HIV care. We retrospectively reviewed routinely collected data from 2016 to 2019 at six urban public health facilities in Uganda. Methods A cross-sectional review of the HIV care database and paper-based TPT registers at six public health facilities in Kampala, Uganda. Estimated trends of prevalence of TPT (given as Isoniazid preventive therapy [IPT]) uptake and treatment completion across the 4 years, among PLHIV aged 15 years and above, and factors associated, were examined using Poisson regression model with robust standard errors using generalized estimating equation (GEE) models. Results On average a total of 43,215 patients aged 15 years and above were eligible for TPT each calendar year at the six health facilities. More than 70% were females and median age was 34 years (inter-quartile range 28 to 41 years on overall). There was consistently low TPT uptake from 2016 to 2018, but as expected, the uptake significantly increased by about 25% (relative increase) from 2.5% of eligible PLHIV in 2018 to 64.8% in 2019 (prevalence of TPT uptake 4.5% (1,746/38,704), 4.4% (1,743/39,630), 2.5% (1,018/40,390), and 64.8% (26,478/40,867) during 2016, 2017, 2018 and 2019 respectively). TPT uptake in 2019 was 26.0 times higher compared to that in 2018 (adjusted prevalence ratio [aPR] = 26.0 [95%CI 24.5, 27.7], P-valueConclusion The targeted 100-day campaign dramatically increased TPT uptake and completion among PLHIV suggesting a viable catch up strategy to meet WHO guidelines.
Open AccessIncreased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: A retrospective review of routinely collected data at six urban public health facilities in Uganda
Introduction Tuberculosis preventive therapy (TPT) effectively decreases rates of tuberculosis reactivation in people living with HIV (PLHIV) who are at increased risk. The Uganda Ministry of Health launched a 100-day campaign to scale-up TPT in PLHIV in July 2019. We sought to examine the effect of the campaign on trends of TPT uptake and characteristics associated with TPT uptake and TPT completion among persons in HIV care. We retrospectively reviewed routinely collected data from 2016 to 2019 at six urban public health facilities in Uganda. Methods A cross-sectional review of the HIV care database and paper-based TPT registers at six public health facilities in Kampala, Uganda. Estimated trends of prevalence of TPT (given as Isoniazid preventive therapy [IPT]) uptake and treatment completion across the 4 years, among PLHIV aged 15 years and above, and factors associated, were examined using Poisson regression model with robust standard errors using generalized estimating equation (GEE) models. Results On average a total of 43,215 patients aged 15 years and above were eligible for TPT each calendar year at the six health facilities. More than 70% were females and median age was 34 years (inter-quartile range 28 to 41 years on overall). There was consistently low TPT uptake from 2016 to 2018, but as expected, the uptake significantly increased by about 25% (relative increase) from 2.5% of eligible PLHIV in 2018 to 64.8% in 2019 (prevalence of TPT uptake 4.5% (1,746/38,704), 4.4% (1,743/39,630), 2.5% (1,018/40,390), and 64.8% (26,478/40,867) during 2016, 2017, 2018 and 2019 respectively). TPT uptake in 2019 was 26.0 times higher compared to that in 2018 (adjusted prevalence ratio [aPR] = 26.0 [95%CI 24.5, 27.7], P-valueConclusion The targeted 100-day campaign dramatically increased TPT uptake and completion among PLHIV suggesting a viable catch up strategy to meet WHO guidelines.